Landmark Trial Tests Whether Chemotherapy Can Be Spared in High-Risk Early Breast Cancer
The new phase 3 RxFINE-Low trial will test whether patients with low genomic risk but high anatomic risk early-stage breast ...
The new phase 3 RxFINE-Low trial will test whether patients with low genomic risk but high anatomic risk early-stage breast ...
The new global phase III AFT-70 NAVIGATE trial will test whether ultrasensitive Signatera MRD blood monitoring can safely guide CDK4/6 ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.